ArticleTranslational perioperative and pain medicine
Major Depressive Disorder and Kappa Opioid Receptor Antagonists.
Article in Translational perioperative and pain medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Strategy for effective analgesia with intravenous buprenorphine in patients with acute postoperative pain.BMC anesthesiology · 2025Pooled it
- Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.Molecular psychiatry · 2020Trial
- Effects of Buprenorphine on Responses to Emotional Stimuli in Individuals with a Range of Mood Symptomatology.The international journal of neuropsychopharmacology · 2018Trial
- Kappa opioid receptor antagonism in neuropsychiatry: from molecular mechanisms to clinical prospects.European archives of psychiatry and clinical neuroscience · 2026Review
- Triazole 187 is a biased KOR agonist that suppresses itch without sedation and induces anxiolytic-like behaviors in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Article
- Targeting mGlyR with nanobodies for depression.Nature communications · 2026Article
- Novel dual kappa/mu opioid ligands based on a tetrahydroisoquinoline-valine hybrid nucleus.Scientific reports · 2025Article
- Safety in treatment: Classical pharmacotherapeutics and new avenues for addressing maternal depression and anxiety during pregnancy.Pharmacological reviews · 2025Review
- Unveiling the link between chronic pain and misuse of opioids and cannabis.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Therapeutic Potential of Buprenorphine in Depression: A Meta-Analysis of Current Evidence.Journal of clinical medicine research · 2024Article
- Pharmacologic hyperreactivity of kappa opioid receptors in periaqueductal gray matter during alcohol withdrawal syndrome in rats.Pharmacological reports : PR · 2023Article
- Potential biomarkers: differentially expressed proteins of the extrinsic coagulation pathway in plasma samples from patients with depression.Bioengineered · 2021Article
- Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder.Journal of clinical medicine · 2021Article
- Ontogenetic Oxycodone Exposure Affects Early Life Communicative Behaviors, Sensorimotor Reflexes, and Weight Trajectory in Mice.Frontiers in behavioral neuroscience · 2021Article
- Perioperative Management of Buprenorphine: Solving the Conundrum.Pain medicine (Malden, Mass.) · 2019Review
- Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?The mental health clinician · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Major depressive disorder (MDD) is a common psychiatric disease worldwide. The clinical use of tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitor (SNRIs) for this condition have been widely accepted, but they were challenged by unacceptable side-effects, potential drug-drug interactions (DDIs) or slow onset/lack of efficacy. The endogenous opioid system is involved in stress and emotion regulatory processes and its role in MDD has been implicated. Although several KOR antagonists including JDTic and PF-04455242 were discontinued in early clinical trials, ALKS 5461 and CERC-501(LY-2456302) survived and entered into Phase-III and Phase-II trials, respectively. Considering the efficacy and safety of early off-label use of buprenorphine in the management of the treatment-resistant depression (TRD), it will be not surprising to predict the potential success of ALKS 5461 (a combination of buprenorphine and ALKS-33) in the near future. Moreover, CERC-501 will be expected to be available as monotherapy or adjuvant therapy with other first-line antidepressants in the treatment of TRD, if ongoing clinical trials continue to provide positive benefit-risk profiles. Emerging new researches might bring more drug candidates targeting the endogenous opioid system to clinical trials to address current challenges in MDD treatment in clinical practice.
Indexed as
Identifiers
27213169PMC4871611W2402044500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.